Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • FDA approves Pfizers...

    FDA approves Pfizers drug for rare blood cancer

    Written by Ruby Khatun Khatun Published On 2017-08-18T10:15:03+05:30  |  Updated On 18 Aug 2017 10:15 AM IST
    FDA approves Pfizers drug for rare blood cancer

    The U.S. Food and Drug Administration (FDA) said on Thursday it approved Pfizer Inc's rare blood cancer drug, Besponsa, with a boxed warning.


    Besponsa was approved to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).


    Based on the typical duration of treatment, the total cost of the drug will be $168,300, before discounts to purchasers, Pfizer told Reuters.


    The list price of a drug is not necessarily what patients actually pay. 'Out-of-pocket' costs vary based on duration of the treatment and individual healthcare plans.


    Besponsa will carry a boxed warning, the severest form of warning by the FDA, saying patients treated with the drug were at a risk of severe liver damage as well as an increased risk of death for patients who take the drug after receiving a certain type of stem cell transplant.


    B-cell precursor ALL is a rapidly progressing cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell.


    Besposa — approved in the European Union earlier this year — is a targeted therapy that binds to B-cell ALL cancer cells that express the CD22 antigen, blocking the growth of cancer cells.


    According to the National Cancer Institute, ALL will affect about 5,970 people in the United States this year and kill about 1,440.


    Pfizer shares were down about 1 percent at $33 on Thursday.




    (Reporting by Divya Grover and Tamara Mathias in Bengaluru; Editing by Shounak Dasgupta)



    acute lymphoblastic leukemiaapprovalB-cell lymphocytesBesponsablood cancercancer cellsdrugEuropean UnionFDAHealthcareNational Cancer InstitutePfizerrarestem cell transplantU.S. Food and Drug Administration
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok